As CRC patients with deficient MMR (dMMR) generally respond better to anti‐PD‐1/PD‐L1 immunotherapy than their MMR‐proficient counterparts [25, 26], we investigated whether there was an association between dMMR status and PD‐L1 expression in CRC. Here, PDCD1 is linked to colorectal carcinoma.